Routy Bertrand, Letendre Caroline, Enot David, Chénard-Poirier Maxime, Mehraj Vikram, Séguin Noémie Charbonneau, Guenda Khaled, Gagnon Kathia, Woerther Paul-Louis, Ghez David, Lachance Silvy
Gustave Roussy Comprehensive Cancer Center, Villejuif, France; Department of Hematology and Stem Cell Transplant Program, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada.
Department of Hematology and Stem Cell Transplant Program, Hôpital Maisonneuve-Rosemont, University of Montreal , Montreal, QC, Canada.
Oncoimmunology. 2016 Dec 27;6(1):e1258506. doi: 10.1080/2162402X.2016.1258506. eCollection 2017.
The intestinal microbiota plays a key role in the pathogenesis of acute graft-versus-host disease (aGVHD). High-dose conditioning regimens given prior to allogeneic hematopoietic stem cell transplantation (aHSCT) modulate the composition of gut microbiota and damage the gut epithelial barrier, resulting in increased systemic inflammation. We assessed whether gut decontamination with antibiotics (ATB) prior to aHSCT influenced the frequency of aGVHD and mortality in 500 patients from two Canadian centers between 2005 and 2012. The rate of grade II-IV aGVHD was higher in the ATB arm compared with the arm without ATB (42% vs 28%; < 0.001). This difference was mainly driven by a 2-fold higher rate of grade II-IV gastrointestinal aGVHD (GI-GVHD) in the ATB arm compared with the arm without ATB (20.7% vs 10.8%; = 0.003). Multivariate analyses adjusted for known aGVHD risk factors revealed that more patients in the ATB group developed clinically significant GI-GVHD and liver aGVHD; adjusted odds ratio (aOR) = 1.83; = 0.023 and aOR = 3.56; = 0.047, respectively. Importantly, median overall survival (OS) was significantly lower in the group receiving ATB and the OS at 10 y remained decreased in the ATB group; adjusted hazard ratio (aHR) = 1.61 ( < 0.001). Without undermining the role of ATB prophylaxis to prevent infection in aHSCT, we have shown that the use of ATB that targets intestinal bacteria is associated with a more severe aGVHD that involves the GI organs and impacts OS. Prospective studies that evaluate the contribution of bacterial decontamination to aGVHD are warranted.
肠道微生物群在急性移植物抗宿主病(aGVHD)的发病机制中起关键作用。异基因造血干细胞移植(aHSCT)前给予的大剂量预处理方案会调节肠道微生物群的组成并损害肠道上皮屏障,导致全身炎症增加。我们评估了2005年至2012年间来自加拿大两个中心的500例患者在aHSCT前使用抗生素(ATB)进行肠道净化是否会影响aGVHD的发生率和死亡率。与未使用ATB的组相比,使用ATB的组中II-IV级aGVHD的发生率更高(42%对28%;<0.001)。这种差异主要是由于使用ATB的组中II-IV级胃肠道aGVHD(GI-GVHD)的发生率比未使用ATB的组高2倍(20.7%对10.8%;=0.003)。对已知的aGVHD危险因素进行多变量分析显示,ATB组中有更多患者发生了具有临床意义的GI-GVHD和肝脏aGVHD;调整后的优势比(aOR)分别为1.83;=0.023和aOR = 3.56;=0.047。重要的是,接受ATB的组的中位总生存期(OS)显著更低,并且ATB组10年时的OS仍然降低;调整后的风险比(aHR)= 1.61(<0.001)。在不削弱ATB预防在aHSCT中预防感染作用的前提下,我们已经表明,针对肠道细菌使用ATB与更严重的aGVHD相关,这种aGVHD累及胃肠道器官并影响OS。有必要进行前瞻性研究来评估细菌净化对aGVHD的影响。